M4H

M4H (formerly known as Ab6) is a humanized IgG1 monoclonal antibody that specifically targets and blocks the transient receptor potential melastatin 4 (TRPM4) channel. Developed by the National Neuroscience Institute in Singapore, M4H was generated through CDR grafting of the mouse monoclonal antibody M4M. Under hypoxic or ischemic conditions, such as those occurring during a stroke, ATP depletion leads to the abnormal activation of TRPM4, causing excessive sodium influx, cell swelling, and oncotic cell death. By blocking TRPM4, M4H prevents these pathological changes, thereby reducing blood-brain barrier leakage, cerebral edema, and neuroinflammation. Preclinical studies in humanized TRPM4 rat models of stroke reperfusion injury have demonstrated that M4H significantly reduces infarct volume and improves functional recovery.

Other names

Ab6Ab-6Ab 6humanized anti-TRPM4 antibody M4Hhumanized monoclonal antibody M4H